Shots:

• The two P-III studies KEEPsAKE-1 & -2 involves assessing Skyrizi (150mg) vs PBO followed by risankizumab (150mg- @24wks.) in patients with active PsA who had an inadequate response or intolerant to at least one biologic therapy and/or non-biologic DMARDs respectively
• Results: ACR20 (57% & 51% vs 34% & 27%); ACR50 (33% & 26% vs 11% & 9%); ACR70 (15% & 12% vs 5% & 6%); PASI 90 (52% & 55% vs 10% & 10%); HAQ-DI (-0.31 & -0.22 vs -0.11 & -0.05); MDA (25% & 26% vs 10% & 11%) respectively
• The safety profile is consistent with the known profile of risankizumab in psoriasis patients. Skyrizi is an IL-23 inhibitor- being developed in collaboration with Boehringer Ingelheim

 ­ Ref: Abbvie | Image: abbvie